Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.

Erlotinib can cause nonscarring hair loss and itchy skin.

Erlotinib may cause scarring hair loss.

EGFR hyperactivation increases sebaceous gland size and sebum production in mice.

Targeting EGFR may help reduce hair loss from chemotherapy.

Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.

EGFR helps mouse hair follicles stop growing by reducing certain growth regulators.

c-kit affects hair growth and color in alopecia areata and androgenetic alopecia.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.

Targeting FGFR-1 with antisense oligonucleotides may help treat baldness by increasing hair follicle activity.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Different forms of the Vitamin D receptor can impact metabolic and hormone issues in Polycystic Ovary Syndrome.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

The most common sign of aging at the gene level is more Ectodysplasin A2 Receptor (EDA2R) being made.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

CD117 and platelet-derived growth factor receptor α may play a role in alopecia areata.